{"entity":{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","aka":[],"tldr":"Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026.","summary":"C4 Therapeutics, based in Watertown, Massachusetts, and listed as CCCC, is a protein degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53 percent response rate in heavily pretreated multiple myeloma and entered phase 2 in 2026. Cemsidomide, built on the MonoDAC platform, with dexamethasone gave that response rate at the 100 microgram dose in relapsed or refractory myeloma at EHA 2026; the phase 2 MOMENTUM trial enrolled its first patient in February 2026 and a phase 1b with elranatamab is ongoing. OnCo links it to multiple myeloma, to PROTACs and molecular glues and glue discovery platforms, to the bottleneck of undruggable drivers, and to ideas on degraders for childhood sarcoma fusion proteins. Whether a next-generation IKZF1/3 degrader beats older drugs of the class in a randomised trial is the open question. The degrader technology page carries the field.","asOf":"2026-09-04","links":[{"label":"EHA 2026 data","url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07284758"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://c4therapeutics.com","ticker":"CCCC","investors":[],"funding":[]},"route":"/companies/c4-therapeutics/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"trial":[{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"idea":[{"id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/"},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/"},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/"},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/"}]}}